SpectraCure AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPEC.ST research report →
Companywww.spectracure.com
SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.
- CEO
- Johannes Swartling
- IPO
- 2015
- Employees
- 16
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $35.07M
- P/E
- -0.63
- P/S
- 0.00
- P/B
- 0.37
- EV/EBITDA
- -1.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -52.16%
- ROIC
- -55.63%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-56,079,000 · -143.78%
- EPS
- $-0.14 · 41.67%
- Op Income
- $-54,353,000
- FCF YoY
- 35.25%
Performance & Tape
- 52W High
- $1.19
- 52W Low
- $0.06
- 50D MA
- $0.08
- 200D MA
- $0.14
- Beta
- 0.26
- Avg Volume
- 1.36M
Get TickerSpark's AI analysis on SPEC.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SPEC.ST Coverage
We haven't published any research on SPEC.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SPEC.ST Report →